◆英語タイトル：Genextra Spa - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8013324
◆発行会社（調査会社）：
GlobalData
◆発行日：2017年11月28日
◆ページ数：35
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：イタリア
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
Summary
Genextra SpA (Genextra) is a pharmaceutical company that discovers and develops therapies for age-related and metabolic diseases. The company develops INT-747 for comb, mono therapy and diabetes, INT- 777 for metabolic syndrome; novel HDAC and HSP90 inhibitors for the treatment of cancer; mjPTP inhibitor and nanoparticles in gas phase to yields. It offers research in life science and to develop novel therapies and tools. The company caters to entrepreneurs and financial institutions in partnership with leading scientists. It operates through its subsidiaries across Italy. Genextra is headquartered in Milano, Lombardia, Italy.
Genextra Spa – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Genextra Spa, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Genextra Spa, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Genextra Spa, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Genextra Spa, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Genextra Spa, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Genextra Spa, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
EryDel Raises Additional USD16.23 million in Series B Financing 10
EryDel Raises US$20 Million In Series B Financing 11
Intercept Pharma Raises US$30 Million In Series C Financing 12
Partnerships 14
Intercept Pharma Extends Agreement with Target Pharma 14
Intercept pharma Enters into Research Agreement with University of Perugia 15
Intercept Pharma Enters Into Co-Development Agreement With Servier 16
Licensing Agreements 17
Dainippon Sumitomo Pharma Enters Into Licensing Agreement With Intercept Pharma For INT-747 17
Equity Offering 19
Intercept Pharma Raises USD367.3 Million in Public Offering of Shares 19
Intercept Pharma Raises USD202 Million in Public Offering of Shares 21
Intercept Pharma Completes Public Offering Of Shares For US$192 Million 23
Intercept Pharma Completes Public Offering Of Shares For US$65.7 Million 25
Intercept Pharma Completes Underwriters’ Exercise Of Over-Allotment Option For US$86 Million 27
Debt Offering 29
Intercept Pharma Raises USD460 Million in Public Offering of 3.25% Notes Due 2023 29
Acquisition 31
Novartis May Acquire Intercept Pharma 31
Genextra Spa – Key Competitors 32
Genextra Spa – Key Employees 33
Genextra Spa – Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35
List of Tables
Genextra Spa, Pharmaceuticals & Healthcare, Key Facts 2
Genextra Spa, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Genextra Spa, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Genextra Spa, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Genextra Spa, Deals By Therapy Area, 2011 to YTD 2017 8
Genextra Spa, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
EryDel Raises Additional USD16.23 million in Series B Financing 10
EryDel Raises US$20 Million In Series B Financing 11
Intercept Pharma Raises US$30 Million In Series C Financing 12
Intercept Pharma Extends Agreement with Target Pharma 14
Intercept pharma Enters into Research Agreement with University of Perugia 15
Intercept Pharma Enters Into Co-Development Agreement With Servier 16
Dainippon Sumitomo Pharma Enters Into Licensing Agreement With Intercept Pharma For INT-747 17
Intercept Pharma Raises USD367.3 Million in Public Offering of Shares 19
Intercept Pharma Raises USD202 Million in Public Offering of Shares 21
Intercept Pharma Completes Public Offering Of Shares For US$192 Million 23
Intercept Pharma Completes Public Offering Of Shares For US$65.7 Million 25
Intercept Pharma Completes Underwriters' Exercise Of Over-Allotment Option For US$86 Million 27
Intercept Pharma Raises USD460 Million in Public Offering of 3.25% Notes Due 2023 29
Novartis May Acquire Intercept Pharma 31
Genextra Spa, Key Competitors 32
Genextra Spa, Key Employees 33
Genextra Spa, Subsidiaries 34
